<DOC>
	<DOCNO>NCT02758392</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics ( PK ) immunogenicity JNJ-61178104 follow single ascend Intravenous ( IV ) dose administration single Subcutaneous ( SC ) dose administration healthy participant .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability JNJ-61178104 Healthy Participants</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , single ascend dose , single site , interventional study . There 5 single ascend dose ( SAD ) IV cohorts 1 SC cohort . Nine participant enrol 5 IV cohort 1 SC cohort participant randomize ratio 2:1 receive JNJ-61178104 placebo . The total duration participant participation approximately 21 week include Screening Visit 4 week prior study drug administration . Participants inpatient period consist 6 days/5 night return study-site Weeks 2 , 3 , 4 , 5 , 7 , 9 , 13 , 17 . Participants evaluate safety throughout study .</detailed_description>
	<criteria>Inclusion Criteria Participant must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study Participant must body weight range 50 Kilogram ( kg ) 100 kg , inclusive , body mass index 19 Kilogram per meter square ( kg/m^2 ) 30 kg/m2 , inclusive Participant must healthy basis clinical laboratory test perform Screening Day1 . If result serum chemistry panel include liver enzyme , hematology panel , urinalysis outside normal reference range , participant may include investigator judge abnormalities deviation normal clinically significant appropriate reasonable population study . This determination must record participant 's medical record document review confirmation investigator Before randomization , woman must childbearing potential : ) Postmenopausal { great ( &gt; ) 45 year age amenorrhea least 12 month age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 International Units Per Litre ( IU/L ) Screening } ; b ) Permanently sterilize ( example , bilateral tubal occlusion , hysterectomy , bilateral salpingectomy , oophorectomy ) ; c ) Otherwise incapable pregnancy Be consider eligible accord follow tuberculosis ( TB ) Screening criterion : ) Have history latent active TB prior Screening ; b ) Have sign symptom suggestive active TB upon medical history and/or physical examination ; c ) Have recent close contact person active TB ; ) Have negative TSpot TB test result Screening Participant currently history clinically significant medical illness medical disorder investigator considers exclude participant , include ( limited ) , neuromuscular , hematological disease , immune deficiency state , cardiac , vascular , metabolic , endocrine , rheumatologic , respiratory disease , hepatic gastrointestinal disease , neurological psychiatric disease , ophthalmological disorder , neoplastic disease , renal urinary tract disease , dermatological disease Participant QT correct accord Fridericia 's formula ( QTcF ) interval &gt; 450 msec , complete leave right bundle branch block , history current evidence additional risk factor torsades de pointes ( example , heart failure , hypokalemia , family history Long QT Syndrome ) Screening Day 1 Participant major surgery , ( example , require general anesthesia ) within 4 month Screening , fully recover surgery , surgery plan time participant expect participate study within 17 week last dose study drug administration Participant plan undergo nonmajor elective surgery within 4 week prior study drug administration end study Participant know suspect intolerance hypersensitivity biologic medication know allergy clinically significant reaction murine , chimeric , human protein , monoclonal antibody antibody fragment , component formulation JNJ61178104 excipients use study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-61178104</keyword>
	<keyword>Placebo</keyword>
	<keyword>Safety</keyword>
</DOC>